A Glimmer of Hope for COPD Sufferers: The Unseen Consequences of Progress The latest clinical trials have yielded promising results for patients with chronic obstructive pulmonary disease (COPD), a condition affecting nearly 16 million adults in the United States.
Tozorakimab, developed by AstraZeneca, has shown significant reductions in moderate and severe COPD symptoms in both former and current smokers.
This breakthrough raises important questions about the environmental and socioeconomic factors contributing to COPD's prevalence.